15 investors back Seoul healthtech in 2026. Korea leads in medical AI and biotech. Most money goes to bio and pharma, with telehealth still tightly limited.
Seoul backs health through bio and AI. Telehealth stays tightly limited here.
Biotech pulls most of the big money. Medical AI is the digital bright spot.
Pharma firms now run their own funds. They pick drug candidates directly.
Cheques run US$500K to US$30M. Bio rounds can run far larger.
Bio VC funding hit a four-year high. More capital now chases proven teams.
Health rounds run on data and trials. Ellty keeps your files in one tracked room.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Korea Investment Partners | VC | US$2M-$15M | Biotech, medical AI, healthcare | kipvc.com |
| Mirae Asset Venture | VC + life-science fund | US$2M-$20M | Biotech, therapeutics | miraeassetvc.com |
| InterVest | VC | US$2M-$15M | Biotech, healthcare, medical AI | intervest.co.kr |
| SV Investment | Bio / health VC | US$1M-$4M | Healthcare, biopharma | svinvestment.co.kr |
| DSC Investment | VC | US$1M-$10M | Biotech, medtech, AI | dscinvestment.com |
| LSK Investment | Life-science VC | US$1M-$8M | Therapeutics, medical devices | lskinvest.com |
| Premier Partners | Growth-VC / PE | US$5M-$30M | Biotech, vaccines, healthcare | premierpartners.co.kr |
| KB Investment | Corporate VC (KB) | US$2M-$15M | Biotech, healthcare, AI | kbic.co.kr |
| Company K Partners | VC | US$1M-$8M | Biotech, drug discovery, health | companyk.com |
| Atinum Investment | VC | US$3M-$20M | Biotech, medical device, health | atinuminvest.co.kr |
| Kakao Ventures | Corporate VC (seed) | US$0.5M-$5M | Digital health, medical AI | kakao.vc |
| Naver D2SF | Corporate VC | US$0.5M-$3M | Medical AI, digital health | d2sf.naver.com |
| SBVA | VC | US$2M-$20M | Healthtech, biotech, AI | sbva.com |
| Samsung Life Science Fund | Pharma corporate VC | US$5M-$30M | Therapeutics, ADCs, AI drugs | samsungventure.co.kr |
| Solidus Investment (JW) | Pharma-strategic VC | US$2M-$15M | Biotech, therapeutics | solidusinvestment.com |
Keep your trial data room ready for every fund
Health funds run long diligence on trials, IP, and approvals. Ellty logs every view so you know who is serious before the call.
Start free 14-day trialWhat a healthtech investor backs
A healthtech investor backs proof and safety. They want real clinical data.
They check trials, approvals, and IP. Store proof in one virtual data room.
They study your science and your team. Ellty features make sharing simple.
They look for a clear payer or buyer. Strong science with no market rarely wins.
Ellty gives each fund one tracked link to your data. You see who read your trial data first.
Large-scale investments concentrated in biotech companies with high exit potential. We need to create a structure where capital spreads to early-stage ventures.
15 Seoul healthtech investors
1. Korea Investment Partners
KIP is a top Korean VC with a deep bio book.
Recent Activity: Backed Orum and Pinetree Therapeutics in 2025
LinkedIn: Korea Investment Partners LinkedIn
Sector Focus: Biotech, medical AI, healthcare
Stage Focus: Seed to growth
Check Size: US$2M-$15M
Location: Seoul
Website: kipvc.com
2. Mirae Asset Venture
Mirae Asset runs a dedicated life-science fund.
Recent Activity: Launched a US$50M US biotech fund in 2024
Sector Focus: Biotech, therapeutics
Stage Focus: Early to growth
Check Size: US$2M-$20M
Location: Seoul
Website: miraeassetvc.com
3. InterVest
InterVest is a large Korean VC strong in bio.
Recent Activity: An early backer of medical-AI leader Lunit
LinkedIn: InterVest LinkedIn
Sector Focus: Biotech, healthcare, medical AI
Stage Focus: Early to growth
Check Size: US$2M-$15M
Location: Seoul
Website: intervest.co.kr
4. SV Investment
SV Investment is a listed bio and health VC.
Recent Activity: Backed Pinetree Therapeutics' US$47M round
Sector Focus: Healthcare, biopharma
Stage Focus: Early to growth
Check Size: US$1M-$4M
Location: Seoul
Website: svinvestment.co.kr
5. DSC Investment
DSC is a listed VC active in biotech and medtech.
Recent Activity: Backed Orum and Pinetree Therapeutics
LinkedIn: DSC Investment LinkedIn
Sector Focus: Biotech, medtech, AI
Stage Focus: Early to growth
Check Size: US$1M-$10M
Location: Seoul
Website: dscinvestment.com
6. LSK Investment
LSK is a life-science specialist VC in Seoul.
Recent Activity: Backed IMBiologics' 2025 Series C round
Sector Focus: Therapeutics, medical devices
Stage Focus: Early to growth
Check Size: US$1M-$8M
Location: Seoul
Website: lskinvest.com
Share one link with every health fund
Ellty shows when KIP or InterVest opens your trial data. Follow up with each fund at the right time.
Start free 14-day trial7. Premier Partners
Premier manages Korea's K-Bio and Vaccine Fund.
Recent Activity: Manages Korea's K-Bio and Vaccine Fund
Sector Focus: Biotech, vaccines, healthcare
Stage Focus: Growth
Check Size: US$5M-$30M
Location: Seoul
Website: premierpartners.co.kr
8. KB Investment
KB Investment is KB Financial Group's VC arm.
Recent Activity: Backed Orum Therapeutics' ~US$100M round
Sector Focus: Biotech, healthcare, AI
Stage Focus: Series A focus
Check Size: US$2M-$15M
Location: Seoul
Website: kbic.co.kr
9. Company K Partners
Company K backs Korean drug-discovery startups.
Recent Activity: Backed Illimis Therapeutics' US$42M round
Sector Focus: Biotech, drug discovery, health
Stage Focus: Series A focus
Check Size: US$1M-$8M
Location: Seoul
Website: companyk.com
10. Atinum Investment
Atinum is a growth VC with a long bio portfolio.
Recent Activity: A growth VC with a long bio portfolio
Sector Focus: Biotech, medical device, health
Stage Focus: Growth
Check Size: US$3M-$20M
Location: Seoul
Website: atinuminvest.co.kr
11. Kakao Ventures
Kakao Ventures backs digital health and medical AI.
Recent Activity: Named digital health and AI a 2026 priority
LinkedIn: Kakao Ventures LinkedIn
Sector Focus: Digital health, medical AI
Stage Focus: Seed
Check Size: US$0.5M-$5M
Location: Seoul
Website: kakao.vc
12. Naver D2SF
Naver D2SF backs medical AI and digital health.
Recent Activity: Backed Soundable Health for acoustic AI
Sector Focus: Medical AI, digital health
Stage Focus: Seed, early
Check Size: US$0.5M-$3M
Location: Seongnam / Seoul
Website: d2sf.naver.com
13. SBVA
SBVA backs healthtech and biotech across Korea.
Recent Activity: Closed a US$150M fund covering healthcare
LinkedIn: SBVA LinkedIn
Sector Focus: Healthtech, biotech, AI
Stage Focus: Early to mid
Check Size: US$2M-$20M
Location: Seoul
Website: sbva.com
14. Samsung Life Science Fund
This is Samsung's strategic bio venture fund.
Recent Activity: Launched a ₩200B third bio fund in 2026
Sector Focus: Therapeutics, ADCs, AI drugs
Stage Focus: Strategic equity
Check Size: US$5M-$30M
Location: Seoul
Website: samsungventure.co.kr
15. Solidus Investment (JW)
Solidus is a bio VC, now part of JW Holdings.
Recent Activity: Bio VC backing Alteogen, now part of JW
Sector Focus: Biotech, therapeutics
Stage Focus: Early to growth
Check Size: US$2M-$15M
Location: Seoul
Website: solidusinvestment.com
Korea's medical AI leaders
Korea leads the world in medical AI. Lunit and Vuno both went public.
Their tools read scans and find cancer. New startups follow that path.
Rich hospital data gives them an edge. Funds back teams that can use it well.
Approved tools win export demand fast. One clearance can open new markets.
These tools build on Korea's wider AI push. See our Seoul AI investors guide too.
Investors want clean trial and scan data. Ellty keeps every file in one place.
Bio and pharma money leads
Bio and pharma drive most health money. Telehealth stays limited by law.
Pharma firms now run their own VC arms. They back drug work directly.
A pharma deal can fund a whole trial. It often comes with a licence option.
A licensing deal can de-risk a round. One partner validates your science.
Trial and IP data need careful due diligence. Keep every file in one place.
Ellty shows who opened each file and when. You learn which backer is serious early.
From clinic pilot to a funded scale-up
A clinic pilot is a strong first step. But each round wants more proof.
Investors check trials, approvals, and demand. Early data alone rarely closes it.
A clean trial file speeds the deal up. Have it ready before the term sheet.
A named hospital partner adds weight. One site can anchor the round.
Read our due diligence timeline guide. Know what each stage will ask.
Watch for due diligence red flags early. Ellty logs who opened each file and when.
How to pitch a Seoul healthtech investor
Lead with real clinical proof.
- 1.Lead with real clinical proof.Health funds want hard data, so open with trial results and outcomes.
- 2.Show trials, approvals, and IP.Safety and science come first, so map your regulatory path clearly.
- 3.Name your first paying clinic or partner.Funds want real demand, so show who already uses and pays for your tool.
- 4.Share one Ellty link to your whole data room.Skip scattered email attachments and track who opens which files in real time.
- 5.Follow up the same day a fund digs in.Ellty flags the moment they open your trial data, so you reach out while interest is high.
How Ellty helps you land a healthtech investor in Seoul
You've shortlisted your Seoul healthtech investors already. Set up a data room before the first call.
- 1.Upload your trial data, IP, and deck.Set access per fund or per partner.
- 2.Share one trackable link with each fund.Each fund gets its own tracked link.
- 3.Watch opens and follow up at the right time.Use Ellty analytics to time each nudge.
Seoul healthtech investor questions
- KIP, InterVest, and DSC back health. Pharma CVCs invest too.
- Cheques run US$0.5M to US$30M in 2026. Bio rounds can run larger.
- No, the law still limits it. Most money goes to bio and AI.
- It has rich health data and talent. Lunit and Vuno lead the way.
- Clinical proof, IP, and a clear path. Strong science and a team.
- Before your very first investor call. Track who opens your trial data.
